Gossamer Bio Aims for September 2026 NDA Submission for Seralutinib After Positive Imaging Data — Gossamer Bio, Inc.

Event summary

Gossamer Bio plans to submit an NDA for seralutinib in PAH by September 2026, following a Pre-NDA Type B meeting with the FDA in mid-June 2026.
PROSERA CT FRI substudy showed statistically significant imaging signals across arterial, venous, and fibrosis-related parameters in PAH patients.
Gossamer Bio launched an exchange offer for $200 million in convertible notes, aiming to reduce debt by $128 million and extend maturity to 2030.
Q1 2026 revenue was $17.0 million, up from $9.9 million in Q1 2025, while net loss widened to $46.7 million from $36.6 million.

The big picture

Gossamer Bio is advancing seralutinib, its lead candidate for pulmonary arterial hypertension, with a strategic focus on regulatory approval. The company's positive imaging data from the PROSERA trial strengthens its case for an NDA submission, while its debt restructuring aims to bolster its financial position ahead of this critical milestone. The biopharmaceutical sector is closely watching how these developments will position Gossamer Bio in the competitive pulmonary hypertension market.

What we're watching

Regulatory Pathway: Whether the FDA's feedback from the Pre-NDA meeting will support Gossamer Bio's planned September 2026 NDA submission for seralutinib.
Clinical Data: How the broader multi-compartment imaging signals from the PROSERA CT FRI substudy will influence regulatory and commercial perceptions of seralutinib.
Financial Flexibility: The pace at which Gossamer Bio can reduce its debt burden and extend its cash runway as it approaches potential NDA submission.